Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes

被引:0
|
作者
A H Ramirez
C M Shaffer
J T Delaney
D P Sexton
S E Levy
M J Rieder
D A Nickerson
A L George
D M Roden
机构
[1] Vanderbilt University,Department of Medicine
[2] Center for Human Genetics Research,Department of Biomedical Informatics
[3] Vanderbilt University,Department of Genome Sciences
[4] Vanderbilt University,Department of Pharmacology
[5] HudsonAlpha Institute for Biotechnology,undefined
[6] University of Washington,undefined
[7] Vanderbilt University,undefined
来源
关键词
adverse drug reaction; next-generation sequencing; sudden cardiac death;
D O I
暂无
中图分类号
学科分类号
摘要
Marked prolongation of the QT interval and polymorphic ventricular tachycardia following medication (drug-induced long QT syndrome, diLQTS) is a severe adverse drug reaction (ADR) that phenocopies congenital long QT syndrome (cLQTS) and is one of the leading causes for drug withdrawal and relabeling. We evaluated the frequency of rare non-synonymous variants in genes contributing to the maintenance of heart rhythm in cases of diLQTS using targeted capture coupled to next-generation sequencing. Eleven of 31 diLQTS subjects (36%) carried a novel missense mutation in genes with known congenital arrhythmia associations or with a known cLQTS mutation. In the 26 Caucasian subjects, 23% carried a highly conserved rare variant predicted to be deleterious to protein function in these genes compared with only 2–4% in public databases (P<0.003). We conclude that the rare variation in genes responsible for congenital arrhythmia syndromes is frequent in diLQTS. Our findings demonstrate that diLQTS is a pharmacogenomic syndrome predisposed by rare genetic variants.
引用
收藏
页码:325 / 329
页数:4
相关论文
共 50 条
  • [1] Novel rare variants in congenital cardiac arrhythmia genes are frequent in drug-induced torsades de pointes
    Ramirez, A. H.
    Shaffer, C. M.
    Delaney, J. T.
    Sexton, D. P.
    Levy, S. E.
    Rieder, M. J.
    Nickerson, D. A.
    George, A. L., Jr.
    Roden, D. M.
    PHARMACOGENOMICS JOURNAL, 2013, 13 (04): : 325 - 329
  • [2] Cellular basis of drug-induced torsades de pointes
    Roden, D. M.
    BRITISH JOURNAL OF PHARMACOLOGY, 2008, 154 (07) : 1502 - 1507
  • [3] Drug-Induced Torsades de Pointes and Genetic Screening
    Noheria, Amit
    JAMA INTERNAL MEDICINE, 2016, 176 (04) : 560 - 561
  • [4] Drug-induced Torsades de Pointes and implications for drug development
    Fenichel, RR
    Malik, M
    Antzelevitch, C
    Sanguinetti, M
    Roden, DM
    Priori, SG
    Ruskin, JN
    Lipicky, RJ
    Cantilena, LR
    JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2004, 15 (04) : 475 - 495
  • [5] Drug-induced torsades de pointes in one patient with congenital long QT syndrome
    Hsieh, MH
    Chen, SA
    Chiang, CE
    Tai, CT
    Lee, SH
    Wen, ZC
    Chang, MS
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 1996, 54 (01) : 85 - 88
  • [6] Targeted Next Generation Exomic Sequencing of Cardiac Electrophysiology Genes in Cases of Drug-Induced Torsades de Pointes
    Ramirez, Andrea H.
    Shaffer, Christian
    Sexton, David P.
    Levy, Shawn
    George, Alfred L.
    Roden, Dan M.
    CIRCULATION, 2010, 122 (21)
  • [7] Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys
    Misner, D. L.
    Frantz, C.
    Guo, L.
    Gralinski, M. R.
    Senese, P. B.
    Ly, J.
    Albassam, M.
    Kolaja, K. L.
    BRITISH JOURNAL OF PHARMACOLOGY, 2012, 165 (08) : 2771 - 2786
  • [8] Drug-induced torsades de pointes: The evolving role of pharmacogenetics
    Fitzgerald, PT
    Ackerman, MJ
    HEART RHYTHM, 2005, 2 : S30 - S37
  • [9] Drug-Induced Torsades de Pointes and Genetic Screening Reply
    Gupta, Arjun
    Pandey, Ambarish
    JAMA INTERNAL MEDICINE, 2016, 176 (04) : 561 - 561
  • [10] Understanding drug-induced torsades de pointes: a genetic stance
    Kannankeril, Prince J.
    EXPERT OPINION ON DRUG SAFETY, 2008, 7 (03) : 231 - 239